Abstract

In the context of evolving therapeutic landscape in mRCC patients (pts) promoting IO and TKI combination, predictive biomarkers of efficacy are necessary. The role of circulating angiogenesis biomarkers (CABs) to predict response to IO has been assessed in the prospective BIONIKK trial.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call